• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pfizer posts mixed Q1 results

May 2, 2017 By Sarah Faulkner

PfizerShares in Pfizer (NYSE:PFE) fell today after the pharma giant missed sales expectations, but beat earnings estimates on Wall Street with its 1st quarter results.

The N.Y.-based company posted profits of $3.12 billion, or 51¢ per share, on sales of $12.78 billion for the 3 months ended March 31, for bottom-line growth of 3% on sales loss of 2% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 69¢, ahead of consensus on The Street, where analysts were looking for sales of $13.09 billion.

“I was pleased with our 1st quarter 2017 financial performance, which was in line with our expectations, and it reinforces our confidence in the business going forward,” chairman & CEO Ian Read said in prepared remarks. “I believe each of our businesses is well positioned within their individual markets with strong portfolios, highly skilled and accomplished leadership and focused strategies. Innovative Health’s core franchises – Prevnar 13, Lyrica, Ibrance, Eliquis, Xeljanz and Xtandi – have strong leadership positions in their respective therapeutic categories and are complemented by new product launches, including Eucrisa and Bavencio, as well as meaningful pipeline progress. Essential Health’s growth opportunities – sterile injectables, biosimilars and emerging markets  – continue to perform in line with our expectations while we refine the business and position it for potential sustainable revenue growth. Finally, we will continue to allocate our capital to initiatives that we believe will maximize value creation.”

Pfizer said it expects to post adjusted EPS of $2.50 to $2.60 for the full year of 2017.

PFE shares were trading at $33.50 apiece today in afternoon trading, down -0.8%.

Analysts suggested that Pfizer will need to consider making deals in order to improve its growth prospects over the coming year.

“Key franchises came in well below expectations, raising concerns about Pfizer’s ability to grow in the absence of M&A,” Goldman Sachs analysts said, according to Reuters.

On a call with investors, Read said he expects the company will do big deals in the future, but that issues like tax and healthcare reform within the U.S. government need to be resolved before any deals can be made. He added that a number of potential deal-making companies are awaiting data that could affect their value.

“We never say never, but I believe the current environment needs to stabilize in order to be an advantageous market for big deals,” he said.

In February, Pfizer finished the sale of its global infusion therapy assets, Hospira (NYSE:HSP), to ICU Medical (NSDQ:ICUI).

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Hospira Inc., ICU Medical, Pfizer Inc.

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS